Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS

G J Ossenkoppele; D A Breems; G Stuessi; Y van Norden; M Bargetzi; B J Biemond; P A von dem Borne; Y Chalandon; J Cloos; D Deeren; M Fehr; B Gjertsen; C Graux; G Huls; J J J W Janssen; A Jaspers; M Jongen-Lavrencic; E de Jongh; S K Klein; M van der Klift; M van Marwijk Kooy; J Maertens; L Michaux; M W M van der Poel; A van Rhenen; L Tick; P Valk; M C Vekemans; W J F M van der Velden; O de Weerdt; T Pabst; M Manz; B Löwenberg; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); Swiss Group for Clinical Cancer Research (SAKK)

doi:10.1038/s41375-020-0994-7

Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS

G J Ossenkoppele^*, D A Breems, G Stuessi, Y van Norden, M Bargetzi, B J Biemond, P A von dem Borne, Y Chalandon, J Cloos, D Deeren, M Fehr, B Gjertsen, C Graux, G Huls, J J J W Janssen, A Jaspers, M Jongen-Lavrencic, E de Jongh, S K Klein, M van der KliftM van Marwijk Kooy, J Maertens, L Michaux, M W M van der Poel, A van Rhenen, L Tick, P Valk, M C Vekemans, W J F M van der Velden, O de Weerdt, T Pabst, M Manz, B Löwenberg, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK)

^*Corresponding author for this work

Research output: Contribution to journal › Erratum / corrigendum / retractions › Academic

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Original language	English
Article number	2820
Pages (from-to)	2820-2820
Number of pages	1
Journal	Leukemia
Volume	34
Issue number	10
DOIs	https://doi.org/10.1038/s41375-020-0994-7
Publication status	Published - Oct 2020

Access to Document

10.1038/s41375-020-0994-7

1 Article

Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
Ossenkoppele, G. J., Breems, D. A., Stuessi, G., van Norden, Y., Bargetzi, M., Biemond, B. J., von dem Borne, P. A., Chalandon, Y., Cloos, J., Deeren, D., Fehr, M., Gjertsen, B., Graux, C., Huls, G., Janssen, J. J. J. W., Jaspers, A., Jongen-Lavrencic, M., de Jongh, E., Klein, S. K. & van der Klift, M. & 26 others, Kooy, M. V., Maertens, J., Micheaux, L., van der Poel, M. W. M., van Rhenen, A., Tick, L., Valk, P., Vekemans, M. C., van der Velden, W. J. F. M., de Weerdt, O., Pabst, T., Manz, M., Lowenberg, B., Havelange, V., Moors, I., van Obberg, F., Maertens, J. A., Hodossy, B., Vansteenweghen, S., Lammertijn, L., Sonet, A., Triffet, A., Passweg, J., Heim, D., Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) & Swiss Group for Clinical Cancer Research (SAKK), 1 Jul 2020, In: Leukemia. 34, 7, p. 1751-1759 9 p.
Research output: Contribution to journal › Article › Academic › peer-review

Cite this

Ossenkoppele, G. J., Breems, D. A., Stuessi, G., van Norden, Y., Bargetzi, M., Biemond, B. J., A von dem Borne, P., Chalandon, Y., Cloos, J., Deeren, D., Fehr, M., Gjertsen, B., Graux, C., Huls, G., Janssen, J. J. J. W., Jaspers, A., Jongen-Lavrencic, M., de Jongh, E., Klein, S. K., ... Swiss Group for Clinical Cancer Research (SAKK) (2020). Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS. Leukemia, 34(10), 2820-2820. Article 2820. https://doi.org/10.1038/s41375-020-0994-7

@article{50370e4cf2ed451ba66704cf1b624d04,

title = "Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS",

abstract = "An amendment to this paper has been published and can be accessed via a link at the top of the paper.",

author = "Ossenkoppele, {G J} and Breems, {D A} and G Stuessi and {van Norden}, Y and M Bargetzi and Biemond, {B J} and {A von dem Borne}, P and Y Chalandon and J Cloos and D Deeren and M Fehr and B Gjertsen and C Graux and G Huls and Janssen, {J J J W} and A Jaspers and M Jongen-Lavrencic and {de Jongh}, E and Klein, {S K} and {van der Klift}, M and {van Marwijk Kooy}, M and J Maertens and L Michaux and {van der Poel}, {M W M} and {van Rhenen}, A and L Tick and P Valk and Vekemans, {M C} and {van der Velden}, {W J F M} and {de Weerdt}, O and T Pabst and M Manz and B L{\"o}wenberg and {Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)} and {Swiss Group for Clinical Cancer Research (SAKK)}",

year = "2020",

month = oct,

doi = "10.1038/s41375-020-0994-7",

language = "English",

volume = "34",

pages = "2820--2820",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "10",

}

Ossenkoppele, GJ, Breems, DA, Stuessi, G, van Norden, Y, Bargetzi, M, Biemond, BJ, A von dem Borne, P, Chalandon, Y, Cloos, J, Deeren, D, Fehr, M, Gjertsen, B, Graux, C, Huls, G, Janssen, JJJW, Jaspers, A, Jongen-Lavrencic, M, de Jongh, E, Klein, SK, van der Klift, M, van Marwijk Kooy, M, Maertens, J, Michaux, L, van der Poel, MWM, van Rhenen, A, Tick, L, Valk, P, Vekemans, MC, van der Velden, WJFM, de Weerdt, O, Pabst, T, Manz, M, Löwenberg, B, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) & Swiss Group for Clinical Cancer Research (SAKK) 2020, 'Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS', Leukemia, vol. 34, no. 10, 2820, pp. 2820-2820. https://doi.org/10.1038/s41375-020-0994-7

TY - JOUR

T1 - Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS

AU - Ossenkoppele, G J

AU - Breems, D A

AU - Stuessi, G

AU - van Norden, Y

AU - Bargetzi, M

AU - Biemond, B J

AU - A von dem Borne, P

AU - Chalandon, Y

AU - Cloos, J

AU - Deeren, D

AU - Fehr, M

AU - Gjertsen, B

AU - Graux, C

AU - Huls, G

AU - Janssen, J J J W

AU - Jaspers, A

AU - Jongen-Lavrencic, M

AU - de Jongh, E

AU - Klein, S K

AU - van der Klift, M

AU - van Marwijk Kooy, M

AU - Maertens, J

AU - Michaux, L

AU - van der Poel, M W M

AU - van Rhenen, A

AU - Tick, L

AU - Valk, P

AU - Vekemans, M C

AU - van der Velden, W J F M

AU - de Weerdt, O

AU - Pabst, T

AU - Manz, M

AU - Löwenberg, B

AU - Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)

AU - Swiss Group for Clinical Cancer Research (SAKK)

PY - 2020/10

Y1 - 2020/10

N2 - An amendment to this paper has been published and can be accessed via a link at the top of the paper.

AB - An amendment to this paper has been published and can be accessed via a link at the top of the paper.

U2 - 10.1038/s41375-020-0994-7

DO - 10.1038/s41375-020-0994-7

M3 - Erratum / corrigendum / retractions

C2 - 32733013

SN - 0887-6924

VL - 34

SP - 2820

EP - 2820

JO - Leukemia

JF - Leukemia

IS - 10

M1 - 2820

ER -

Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS

Abstract

Access to Document

Fingerprint

Research output

Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS

Cite this